Medicare Enrolled

Dr. Michael Morse, M.D.

Hematology & Oncology · Durham, NC
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
2100 ERWIN RD, Durham, NC 27710
9196204467
In practice since 2006 (19 years)
NPI: 1588748479 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Morse from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Morse? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Morse

Dr. Michael Morse is a hematology & oncology specialist in Durham, NC, with 19 years of NPI registration. Based on federal Medicare data, Dr. Morse performed 634 Medicare services across 436 unique beneficiaries.

Between the years covered by Open Payments, Dr. Morse received a total of $2,387,811 from 47 pharmaceutical and/or device companies across 2014 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Morse is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 27% volume in NC $2,387,811 industry payments

Medicare Practice Summary

Medicare Utilization ↗
634
Medicare services
Top 27% in NC for hematology & oncology
436
Unique beneficiaries
$87
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~33 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
266 $68 $255
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
218 $102 $344
New patient office visit, complex (60-74 min) 88 $125 $490
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
49 $61 $174
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
13 $49 $172
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$2,387,811
Total received (2018-2024)
Avg $341,116/year across 7 years
Top 0% in NC for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
2,014
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,237,841 (93.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$144,529 (6.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,441 (0.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$490,289
2023
$326,835
2022
$332,462
2021
$298,298
2020
$151,223
2019
$405,109
2018
$383,596

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Ipsen Biopharmaceuticals, Inc
$95,099
TAIHO ONCOLOGY, INC.
$91,457
AstraZeneca Pharmaceuticals LP
$90,381
Eisai Inc.
$62,476
JAZZ PHARMACEUTICALS INC.
$56,829
Incyte Corporation
$40,248
Exelixis Inc.
$38,022
SERVIER PHARMACEUTICALS LLC
$10,319
Shionogi Inc
$4,209
Daiichi Sankyo Inc.
$525
LANTHEUS MEDICAL IMAGING, INC.
$400
Novartis Pharmaceuticals Corporation
$148
Epizyme, Inc.
$130
Genentech USA, Inc.
$45
Top 3 companies account for 56.5% of 2024 payments
All-time payments by company (2018-2024) ›
Ipsen Biopharmaceuticals, Inc
$364,221
Genentech USA, Inc.
$305,105
Taiho Oncology, Inc.
$262,623
AstraZeneca Pharmaceuticals LP
$225,406
Exelixis Inc.
$215,359
Eisai Inc.
$174,193
Lexicon Pharmaceuticals, Inc.
$128,074
TAIHO ONCOLOGY, INC.
$110,067
Advanced Accelerator Applications
$66,871
SERVIER PHARMACEUTICALS LLC
$65,308
JAZZ PHARMACEUTICALS INC.
$56,829
Servier Pharmaceuticals LLC
$55,673
Seagen Inc.
$53,634
EISAI INC.
$50,986
Incyte Corporation
$40,331
Celgene Corporation
$36,912
Novartis Pharmaceuticals Corporation
$33,281
Daiichi Sankyo Inc.
$27,927
Merck Sharp & Dohme Corporation
$17,032
TerSera Therapeutics LLC
$14,309
Bayer HealthCare Pharmaceuticals Inc.
$10,556
Shionogi Inc
$8,209
Genentech, Inc.
$7,745
Sun Pharmaceutical Industries Inc.
$7,200
Regeneron Pharmaceuticals, Inc.
$6,236
GENZYME CORPORATION
$5,939
Agios Pharmaceuticals, Inc.
$5,163
F. Hoffmann-La Roche AG
$4,950
Terumo BCT, Inc.
$4,796
Mylan Institutional Inc.
$4,576
ARRAY BIOPHARMA INC
$4,410
G1 Therapeutics, Inc.
$3,601
Helsinn Therapeutics (U.S.), Inc.
$3,240
Curium US LLC
$1,650
Clovis Oncology, Inc.
$1,554
AstraZeneca UK Limited
$1,398
Eli Lilly and Company
$550
BeiGene USA, Inc.
$450
LANTHEUS MEDICAL IMAGING, INC.
$400
BeiGene, Ltd.
$375
COMSORT, Inc
$150
Epizyme, Inc.
$130
GlaxoSmithKline, LLC.
$100
EMD Serono, Inc.
$95
INTERCEPT PHARMACEUTICALS, INC.
$91
ABIOMED
$85
Biogen, Inc.
$20
Top 3 companies account for 39.0% of all-time payments
Associated products mentioned in payments ›
AFINITOR · Abraxane · Avastin · BRAFTOVI · BRUKINSA · BYNFEZIA PEN · CABOMETYX · COSELA · Cabometyx · Detectnet · ENHERTU · Enhertu · Fulphila · IMFINZI · Impella · KEYTRUDA · LIBTAYO · LONSURF · LUTATHERA · LUTATHERA (lutetium Lu 177 dotatate) · Lenvima · Lonsurf · Lucitanib · Lutathera · Nexavar · OCALIVA · ONCASPAR · ONIVYDE · Onivyde · PEMAZYRE · PLUVICTO · Rebif · SANDOSTATIN LAR · SOMATULINE DEPOT · Somatuline Depot · Stivarga · TECENTRIQ · TIBSOVO · TRUSELTIQ · TUKYSA · Tecentriq · Tibsovo · Tislelizumab · VUMERITY · Xermelo · ZIIHERA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for hematology & oncology in NC.

Looking for a hematology & oncology specialist in Durham?
Compare hematology & oncology specialists in the Durham area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Morse is a clinical cardiology specialist, with above-average Medicare volume (top 27% in NC), with speaking/promotional industry engagement in the top 0% of NC peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Morse experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Morse performed 266 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Morse receive payments from pharmaceutical companies?
Yes. Dr. Morse received a total of $2,387,811 from 47 companies across 2,014 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Morse's costs compare to other hematology & oncology specialists in Durham?
Dr. Morse's average Medicare payment per service is $87. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Morse) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →